GHRP-6 vs Ipamorelin.

GHRP-6 (growth hormone-releasing peptide-6) is a synthetic hexapeptide with the sequence His-D-Trp-Ala-Trp-D-Phe-Lys-NH2. First described by endocrinologist Cyril Y. Bowers and colleagues in the mid-1980s, it was the prototype of the growth hormone secretagogue (GHS) class and the chemical ancestor of later peptides such as GHRP-2, hexarelin, and ipamorelin. It is not a hormone replacement; rather, it provokes the body's own pituitary to release growth hormone.

Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) belonging to the growth hormone-releasing peptide (GHRP) class, sometimes described as a "third-generation" GHRP. Derived from the earlier secretagogue GHRP-1, it acts as a ghrelin mimetic and was characterized by Novo Nordisk researchers in the late 1990s as the first GHRP-receptor agonist with selectivity for growth hormone (GH) release approaching that of GHRH. It has no approved therapeutic indication and exists as an investigational/research compound.

GHRP-6 is a synthetic agonist of the growth hormone secretagogue receptor 1a (GHS-R1a), the G-protein-coupled receptor cloned in 1996 whose endogenous ligand, ghrelin, was identified in 1999. Receptor activation drives phospholipase C signaling, raising inositol trisphosphate and diacylglycerol, mobilizing intracellular calcium and activating protein kinase C, which triggers GH release from somatotrophs. This pathway is distinct from and synergistic with GHRH (which signals through cAMP/PKA), and GHRP-6 also acts on the hypothalamus to amplify GHRH tone and suppress somatostatin. Separately, GHRP-6 binds the scavenger receptor CD36, which is implicated in its proposed cytoprotective and anti-ischemic effects independent of GH release. It also stimulates appetite (via NPY/AgRP arcuate neurons) and can transiently raise cortisol and prolactin.

Ipamorelin is a selective agonist of the growth hormone secretagogue receptor type 1a (GHS-R1a), the same G-protein-coupled receptor activated by the endogenous hormone ghrelin. Binding at the pituitary (and hypothalamus) triggers GH release through a GHRP-like pathway distinct from, but synergistic with, GHRH signaling; pharmacological profiling with GHRH and GHRP antagonists showed its action is mediated via the GHRP-type receptor rather than the GHRH receptor. Its defining feature is selectivity: in the original characterization it released GH with potency comparable to GHRP-6 but, unlike older GHRPs, did not meaningfully raise ACTH, cortisol, FSH, LH, prolactin, or TSH, even at doses far above the ED50 for GH release.

In humans, the best-established data are pharmacological/diagnostic: GHRP-6 reliably and synergistically stimulates GH secretion (especially combined with GHRH) and was studied as a GH-provocative agent and probe of the somatotropic axis in the 1990s. Beyond GH provocation, the much-publicized cytoprotective, cardioprotective, and wound/scar-reducing claims rest almost entirely on preclinical work: rodent myocardial infarction and reperfusion models, a rat/rabbit wound and hypertrophic-scar study (Plastic Surgery International, 2016, animal-only), and doxorubicin-cardiotoxicity models. A Clinical Science (2006) paper proposed GHRP-6 for prevention of multiple organ failure, but this remained largely conceptual/preclinical. There are no large, completed, peer-reviewed randomized human trials demonstrating clinical benefit for cardioprotection, healing, or body composition; the human-versus-animal gap here is wide and should not be glossed over.

The foundational evidence is preclinical: Raun et al. (Eur J Endocrinol, 1998) characterized ipamorelin in rats and isolated pituitary cells, establishing GH selectivity over ACTH/cortisol and other pituitary hormones. Subsequent animal work explored non-endocrine effects via GHS-R1a; for example, Venkova et al. (J Pharmacol Exp Ther, 2009) reported prokinetic/anti-ileus activity in a rodent model of postoperative ileus. The principal human data come from a single industry-sponsored (Helsinn Therapeutics) randomized, double-blind, placebo-controlled proof-of-concept trial in bowel-resection patients (Beck et al., Int J Colorectal Dis, 2014; ClinicalTrials.gov NCT00672074), where the primary composite gastrointestinal-recovery endpoint did not reach statistical significance, though some secondary measures trended favorably. There are no large, controlled human trials demonstrating efficacy for muscle growth, anti-aging, fat loss, bone density, or body composition in people; widely repeated claims in those areas rest on mechanism and animal data, not human outcome trials, and the postoperative-ileus program did not advance to Phase III.

Documented effects in human GH-testing studies include marked stimulation of appetite and transient, usually modest, increases in cortisol and prolactin alongside the intended GH rise, reflecting limited receptor selectivity compared with newer agents like ipamorelin. Because GHS-R1a agonism raises GH and downstream IGF-1, theoretical concerns include fluid retention, insulin resistance/altered glucose handling, and the general caution that sustained GH/IGF-1 elevation could promote growth of existing tumors; these long-term risks are not well characterized for GHRP-6 specifically. There are no robust long-term human safety data, no established safety in pregnancy, and product purity/identity is a major real-world hazard since material sold for "research" is unregulated. No dosing or administration guidance is provided here.

Human safety data are limited to small, short-duration trials; the bowel-resection study used intravenous administration in a hospital setting and did not establish a long-term safety profile. As a GH/IGF-1-axis stimulant, plausible class-related concerns include effects on insulin sensitivity and blood glucose, fluid retention, and theoretical risks tied to chronically elevated GH/IGF-1 (e.g., relevant to people with cancer or active proliferative conditions), though these have not been well characterized for ipamorelin specifically in humans. Because much non-clinical material is produced as unregulated "research chemical" powder, real-world risks also include impurity, mislabeling, and lack of sterility/quality control. Long-term consequences of repeated use in humans are essentially unknown.

GHRP-6 is not approved by the FDA (or other major regulators) for any therapeutic indication and is an investigational/research-use-only compound. As a growth hormone secretagogue, it falls under substances prohibited in sport at all times by the World Anti-Doping Agency (WADA).

Ipamorelin is not approved by the FDA (or other major regulators) for any indication; it remains an investigational/research-use compound and was the subject of FDA pharmacy-compounding review activity rather than drug approval. It is prohibited in sport by the World Anti-Doping Agency at all times as a growth hormone secretagogue under category S2 (Peptide Hormones, Growth Factors, and Mimetics).